Authorities in Congo approve new vaccines to combat mpox surge | ANG
  • July 16, 2024

Sports:Argentina claims 16th Copa America Championship with 1-0 win over Colombia

Argentina clinched its second consecutive Copa America title by defeating Colombia 1-0 on Sunday night with Lautaro Martínez’s 112th-minute goal, despite Lionel Messi’s injury in the second half. Messi suffered a …

Business:Kenya to cut spending by nearly 2% in revised budget

Kenya plans to reduce its 2024-25 spending by 1.9% and widen the fiscal deficit to 3.6% of GDP, following the rollback of tax hikes due to protests. In response to protests …

Vote counting begins in Rwanda’s presidential election

Vote counting has begun in Rwanda following the closure of polling stations on Monday in a presidential election poised to extend President Paul Kagame’s long tenure. Kagame, who has led the …

Authorities in the Democratic Republic of Congo have responded to a significant increase in mpox cases and the emergence of a more virulent strain by approving the use of two new vaccines.

Since the start of last year, Congo has reported over 20,000 cases of mpox , with more than 1,000 deaths, primarily affecting children. Mpox, a viral infection spread through close contact, presents flu-like symptoms and can lead to pus-filled lesions, with severe cases proving fatal.

The World Health Organization (WHO) and scientists recently highlighted a new, more dangerous strain spreading in Congo’s South Kivu province. In response, regulatory authorities have granted emergency use authorization for two vaccines: Jynneos, developed by Bavarian Nordic, and LC16, produced by KM Biologics. This decision follows rigorous evaluation by relevant authorities and stakeholders involved in the authorization process.

Congo, one of the world’s poorest countries, first reported a human case of Mpox in 1970 but has historically lacked widespread access to vaccines or treatments for the disease, except through limited clinical trials.

Leave a Reply

Your email address will not be published. Required fields are marked *